Paul A R, Engstrom P F, Weiner L M, Steplewski Z, Koprowski H
Hybridoma. 1986 Jul;5 Suppl 1:S171-4.
Between 1/85 and 3/86, 16 patients with advanced measurable or evaluable pancreatic carcinoma were treated with mouse monoclonal antibody consisting of a single dose of 400 mg 17-1A immunoglobulin given intravenously. None of the eight patients who received monoclonal antibody alone had any subjective or objective benefit. Two of the eight patients who received a combination of monoclonal antibody and 5-fluorouracil, adriamycin and mitomycin (F.A.M.) chemotherapy had clinically useful partial responses lasting 11 months and 7 months respectively. One of these patients, whose initial treatment consisted of an 8-week cycle of F.A.M. chemotherapy, had progressive deterioration as evidenced by weight loss and persistent abnormality of his CT scan, and then achieved a partial response following a single injection of monoclonal antibody while chemotherapy was continued. His response lasted 11 months. There was no toxicity associated with the administration of monoclonal antibody, and the F.A.M. chemotherapy was well-tolerated with moderate and acceptable hematologic toxicity and mild gastrointestinal side effects. There were no treatment-related deaths.
在1985年1月至1986年3月期间，16例患有晚期可测量或可评估胰腺癌的患者接受了小鼠单克隆抗体治疗，静脉注射单剂量400毫克17-1A免疫球蛋白。仅接受单克隆抗体治疗的8例患者均未获得任何主观或客观益处。接受单克隆抗体与5-氟尿嘧啶、阿霉素和丝裂霉素（F.A.M.）联合化疗的8例患者中有2例出现临床上有用的部分缓解，分别持续11个月和7个月。其中1例患者最初接受了为期8周的F.A.M.化疗周期，体重减轻和CT扫描持续异常表明病情进展，随后在继续化疗的同时单次注射单克隆抗体后出现部分缓解。他的缓解持续了11个月。单克隆抗体给药无毒性，F.A.M.化疗耐受性良好，血液学毒性中等且可接受，胃肠道副作用轻微。无治疗相关死亡。
